ArticleVeterinary medicine and science2026
The Effect of Ketamine, Xylazine, and Ketamine/Xylazine Administration on SCN5A (Nav1.5) Gene Expression in Pigeons.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND
objectiveVoltage-gated sodium channels, particularly Nav1.5 encoded by the SCN5A gene, play essential roles in neuronal conduction and cardiac function. Given the widespread use of anaesthetic agents such as ketamine and xylazine in animal studies, this study aimed to evaluate their effects on SCN5A gene expression in pigeon heart tissue.
methodsA total of 20 healthy male and female pigeons (Columba livia) were examined, weighing between 300 and 400 g and aged 6 to 24 months. The birds were randomly divided into four groups of 5, including a control group received normal saline solution (0.9%) at a dose of 1 mL/kg (IM) (group 1), ketamine (60 mg/kg, IM) (group 2), xylazine (16 mg/kg, IM) (group 3), and a combination of ketamine (30 mg/kg, IM) and xylazine (8 mg/kg, IM) (group 4). To study the expression level of the SCN5A gene in pigeon heart tissue, total RNA was first extracted from the tissue samples. Then, the extracted RNA was converted to cDNA, and using quantitative PCR reaction (RT-qPCR) and specific primers, the expression level of the target gene was measured quantitatively and accurately. The obtained data were analysed and compared using the relative method (ΔCt).
resultsThe melting curve analysis revealed a single, sharp peak at approximately 85°C, with no secondary peaks or shoulders, indicating specific amplification and the absence of primer-dimer or non-specific products. The primer efficiency was determined using a standard curve generated from serial dilutions of cDNA. The slope was -3.01, and the amplification efficiency was calculated as 98.89%, which falls within the acceptable range (90%-110%), confirming high PCR efficiency and the absence of inhibitors. The statistical analysis showed no significant difference in SCN5A gene expression between the treatment groups.
conclusionIn conclusion, ketamine, xylazine, and ketamine/xylazine administration did not result in a statistically significant difference in SCN5A expression under the specific experimental conditions tested. Nonetheless, the observed trends warrant further investigation in larger studies or in other target tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.